Quick Answer
Virax Biolabs Group Ltd reported Total Assets of $6.43 million for fiscal year 2025.
Virax Biolabs Group Ltd — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $6.43M +17.2% |
$5.48M -44.1% |
$9.81M +20046.2% |
$48.7K +22.9% |
$39.6K |
| R&D Expense | $1.78M +13.9% |
$1.56M -28.3% |
$2.18M +402.4% |
$433.7K +260.8% |
$120.2K |
| Gross Profit | -$53.1K -204.9% |
$50.6K +3806.2% |
-$1.4K | — | -$9.4K |
- Virax Biolabs Group Ltd reported Total Assets of $6.43 million for fiscal year 2025.
- Virax Biolabs Group Ltd showed an increase of +17.2% in Total Assets compared to the prior fiscal year.
- Virax Biolabs Group Ltd reported R&D Expense of $1.78 million for fiscal year 2025.
- Virax Biolabs Group Ltd showed an increase of +13.9% in R&D Expense compared to the prior fiscal year.
- Virax Biolabs Group Ltd reported Gross Profit of -$53.1 thousand for fiscal year 2025.
- Virax Biolabs Group Ltd showed a decrease of -204.9% in Gross Profit compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: